Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024

The global alpha-1 antitrypsin deficiency augmentation therapy market has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.

The global alpha-1 antitrypsin deficiency augmentation therapy market is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.

The alpha-1 antitrypsin deficiency augmentation therapy market is experiencing growth due to the rising prevalence of respiratory diseases. Respiratory diseases encompass a range of conditions affecting the lungs and the respiratory system, leading to breathing difficulties and compromised lung function. Alpha-1 antitrypsin deficiency augmentation therapy plays a crucial role in addressing respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. This therapy restores the balance of protease-antiprotease activity in the lungs, shielding lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. Notably, according to data from the Centers for Disease Control and Prevention as of March 2023, there were 8,300 reported cases of tuberculosis (TB) in the United States in 2022, marking an increase from the 7,874 cases recorded in 2021. As such, the growing prevalence of respiratory diseases is a key driver for the alpha-1 antitrypsin deficiency augmentation therapy market.

Anticipated growth in the alpha-1 antitrypsin deficiency augmentation therapy market is linked to the escalation in the number of clinical trials. Clinical trials represent essential biomedical or behavioral research studies conducted with human participants to address specific questions about interventions, encompassing new treatments and known interventions necessitating further evaluation and comparison. These trials hold immense significance in the development and approval of novel therapies and medications for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The surge in clinical trials signifies a heightened interest in the development of fresh AATD therapies, potentially leading to the introduction of more effective treatments in the market. For instance, a report by Xtalks as of May 2023 reveals that there were 452,604 clinical studies registered on ClinicalTrials.gov. This number represents a notable increase from the over 365,000 registered trials documented in early 2021. Consequently, the upsurge in clinical trials is a driving force behind the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

The future growth of the alpha-1 antitrypsin deficiency augmentation therapy market faces potential limitations due to the availability of only a limited number of approved medications. This constraint can restrict the treatment options accessible to both patients and healthcare providers. Currently, augmentation therapy with purified intravenous alpha-1 antitrypsin is the sole approved treatment for Alpha-1 Antitrypsin Deficiency (AATD). For example, data from the COPD Foundation, a nonprofit organization based in the United States, reveals that annual medical expenses for individuals utilizing augmentation therapy for AATD amount to $127,537, while non-users incur expenses of $15,874. Approximately 75.3% of patients opt for augmentation therapy. Consequently, the limited availability of approved medications acts as a hindrance to the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Prominent companies operating in the acute respiratory distress syndrome (ARDS) market are placing their focus on the development of innovative therapies, particularly those rooted in recombinant technology-based drug development, to maintain their competitive position in the market. Recombinant DNA technology is utilized to create therapeutic pharmaceuticals via recombinant technology-based drug development. This approach involves modifying the DNA of living organisms to synthesize specific proteins. As an illustration, in March 2022, Inhibrx Inc., a biotechnology company based in the United States, announced the U.S. Food and Drug Administration's (FDA) grant of orphan drug designation to INBRX-101 for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101 represents a recombinant human AAT-Fc fusion protein designed for potential once-monthly dosing to safely achieve and maintain AAT levels comparable to those found in healthy individuals.

In January 2023, GlaxoSmithKline PLC, a United Kingdom-based pharmaceutical and biotechnology company, made a significant investment by acquiring an 11% stake in Wave Life Sciences Ltd. for $50 million. This strategic move aims to leverage GSK's expertise in human genetics, global development, and commercial capabilities in collaboration with Wave's proprietary discovery and drug development platform, PRISMTM. The objective is to expedite the progress of oligonucleotide therapeutics for genetically determined diseases, including the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Wave Life Sciences Ltd. is a clinical-stage RNA medicine company based in the United States, specializing in the development of drugs for AATD and other conditions.

Major players in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2023. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the alpha-1 antitrypsin deficiency augmentation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products used in alpha-1 antitrypsin deficiency augmentation therapy include Glassia, Aralast NP, Prolastin C, Zemaira, and Respreeza. Glassia, for instance, is a medication comprising human Alpha1-Proteinase inhibitors (Alpha1-PI) and is indicated for the treatment of lung disease (emphysema) in adults with severe alpha1-antitrypsin (Alpha1) deficiency. These therapeutic products are administered through various methods, including oral, injection, and inhalation, and are typically provided in healthcare settings such as hospitals, specialty clinics, and more.

This report provides alpha-1 antitrypsin deficiency augmentation therapy market statistics, including alpha-1 antitrypsin deficiency augmentation therapy industry global market size, regional shares, competitors with an alpha-1 antitrypsin deficiency augmentation therapy market share, detailed alpha-1 antitrypsin deficiency augmentation therapy market segments, market trends and opportunities and any further data you may need to thrive in the alpha-1 antitrypsin deficiency augmentation therapy industry. This alpha-1 antitrypsin deficiency augmentation therapy market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The alpha-1 antitrypsin deficiency augmentation therapy market consists of sales of Fazirsiran and RNA interference (RNAi) therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.